CytoDyn Inc (OTCMKTS:CYDY) Stock On Radar As President Takes Medical Leave of Absence
On May 25, 2023, Biotech firm developing leronlimab, CytoDyn Inc (OTCMKTS:CYDY) announced that Dr. Cyrus Arman, the firm’s President, has taken a medical leave of absence.
On Wednesday, CYDY stock increased 0.87% to $0.2620 with 523.96K shares, compared to volume of 1.40 million shares. The stock moved within a range of $0.2520 – 0.2900 after opening trade at $0.2520.
CytoDyn Announces President Takes Medical Leave of Absence
Antonio Migliarese, the firm’s Chief Financial Officer, will be the interim President during Dr. Arman’s absence. Mr. Migliarese would be supported by the firm’s recently appointed Chief Medical Officer, Dr. Melissa Palmer. Furthermore, Dr. Salah Kivlighn, who joined as the firm’s clinical and strategic advisor, will be providing support to ensurethe use of leronlimab in the HIV population.
CytoDyn Inc is planning to host an investment community webcast, which would be announced in the near future. Dr. Palmer, an internationally renowned Hepatologist and experienced industry executive, has been in leadership positions in various pharmaceutical and biotech companies.
In her previous stints, Dr. Palmer led the global development of NASH as well as other liver disease programs. A clinical professor at NYU Langone Medical Center, she was also the director of Hepatology at NYU Plainview, NY.
Dr. Palmer was a solo medical practitioner treating patients for over two decades. She served as a hepatology consultant to over 60 pharmaceutical and biotech companies and was a primary investigator for numerous clinical trials in liver diseases.
An author of over one hundred abstracts, publications, manuscripts, and book chapters, she has also authored the best-selling book “Dr. Melissa Palmer’s Guide to Hepatitis and Liver Disease.”